This is the current revision of this page, as edited by LegionMammal978 (talk | contribs) at 22:47, 27 April 2023 (move systematic name). The present address (URL) is a permanent link to this version.
Revision as of 22:47, 27 April 2023 by LegionMammal978 (talk | contribs) (move systematic name)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Names | |
---|---|
IUPAC name 7-Methylguanosin-7-ium | |
Systematic IUPAC name 2-Amino-9--7-methyl-6-oxo-6,9-dihydro-1H-purin-7-ium | |
Other names N7-Methylguanosine; 2-Amino-1,6-dihydro-7-methyl-6-oxo-9-β-D-ribofuranosylpurinium | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
Abbreviations | m7G; mG |
ChEBI | |
ChemSpider | |
PubChem CID | |
UNII | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C11H16N5O5 |
Molar mass | 298.279 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references |
7-Methylguanosine (mG) is a modified purine nucleoside. It is a methylated version of guanosine and when found in human urine, it may be a biomarker of some types of cancer. In the RNAs, 7-methylguanosine have been used to study and examine the reaction evolving methylguanosine. It also plays a role in mRNA as a blocking group at its 5´-end.
See also
References
- Reynaud, C; Bruno, C; Boullanger, P; Grange, J; Barbesti, S; Niveleau, A (1992). "Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies". Cancer Letters. 61 (3): 255–62. doi:10.1016/0304-3835(92)90296-8. PMID 1739950.
External links
- Metabocard for 7-Methylguanosine (HMDB01107), Human Metabolome Database, University of Alberta
This article about an organic compound is a stub. You can help Misplaced Pages by expanding it. |